Emerging Genomic Applications in Coronary Artery Disease  by Damani, Samir B. & Topol, Eric J.
c2
d
t

s
y
p
c
e
p
F
a
c
M
5
t
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 4 , N O . 5 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 0 . 1 2 . 0 1 6STATE-OF-THE-ART PAPER
Emerging Genomic Applications in
Coronary Artery Disease
Samir B. Damani, MD, PHARMD, Eric J. Topol, MD
La Jolla, California
Over the last 4 years, an unprecedented number of studies illuminating the genomic underpinnings of
common “polygenic” diseases including coronary artery disease have been published. Notably, these
studies have established numerous deoxyribonucleic acid (DNA) variants within or near chromosome
9p21.3, the LPA, CXADR, and APOE genes, to name a few, as key coronary artery disease and sudden
ardiac death susceptibility markers. Most importantly, many of these DNA variants confer over a
-fold increase in risk for coronary artery disease, myocardial infarction, and ventricular ﬁbrillation. Ad-
itionally, loss-of-function variants in the hepatic cytochrome 2C19 system have now been found to be
he predominant genetic mediators of clopidogrel antiplatelet response, with variant carriers having a
3-fold increase in risk for stent thrombosis. In the near future, many additional rare polymorphisms,
tructural variants, and tissue-speciﬁc epigenetic features of the human genome including DNA meth-
lation, histone modiﬁcations, and chromatin state will emerge as signiﬁcant contributors to disease
athogenesis and drug response. In aggregate, these ﬁndings will have the potential to radically
hange the practice of cardiovascular medicine. However, only the individual clinician can ultimately
nable the translation of these important discoveries to systematic implementation in clinical
ractice. (J Am Coll Cardiol Intv 2011;4:473–82) © 2011 by the American College of Cardiology
oundationThe publication of the initial draft of the human
genome sequence in 2000 involved a multinational
decade-long effort at a price tag of over $3 billion
(1). Now, commercial platforms can sequence
whole genomes from several individuals in a day at
a tiny fraction of that cost. Instead of $10,000 for
sequencing 1 million deoxyribonucleic acid (DNA)
bases, the cost is $0.01 (1,2). These technological
dvances combined with a detailed catalog of
ommon human variation provided by the Hap-
ap Project has spawned the publication of over
50 genome-wide association studies (GWAS)
hat have strongly linked nearly 800 gene variants
o over 150 common polygenic diseases and com-
From the Division of Cardiovascular Diseases, Scripps Clinic, Scripps
Translational Science Institute and the Scripps Research Institute, La
Jolla, California. Both authors have received funding from NIH/NCRR/
CTSA/UL1 RR025774. Dr. Topol has served as a consultant to
Sanofi-Aventis, Daiichi Sankyo, and Quest Diagnostics.
Manuscript received July 30, 2010; revised manuscript received December
20, 2010, accepted December 26, 2010.plex traits (3–5). These studies have also identified
numerous highly predictive pharmacogenetic
markers of drug response and toxicity (6–9). To-
gether, these findings have the potential to radi-
cally change the practice of medicine (4). This
review will detail the current discoveries in the field
of translational genomics that have potential ram-
ifications in the prevention and treatment of pa-
tients with ischemic heart disease (IHD).
Analyzing the Genome
Before commencing with a detailed discussion on
the specific applications of genome-based medi-
cine, it is important to first highlight several key
concepts regarding the heritability of traits. Mono-
genic, rare, “simple” Mendelian traits segregate in
autosomal dominant, recessive, X-linked, or mito-
chondrial bases. These relatively infrequent disor-
ders are typically caused by rare, deterministic
genetic mutations. Historical examples of such
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474traits in cardiovascular medicine include hypertrophic car-
diomyopathy, long QT syndromes, and familial hypercho-
lesterolemia (10). In contrast, “complex” traits are common
and arise from elaborate gene-gene and gene-environmental
interactions and confer risk for disease in a probabilistic
manner (11). By far, the most diseases in clinical practice
today are complex traits and include disorders such as
diabetes, myocardial infarction (MI), atherosclerotic coro-
nary artery disease (CAD), and various cancers.
Incremental decoding of the genomic basis of complex
traits will require many years of collaborative research efforts
by clinicians and scientists and will never be complete
(4,12). This is primarily because of the sheer complexity
involved in analyzing the 6 bil-
lion base pairs, over 15 million
single nucleotide polymor-
phisms (SNPs), and hundreds of
thousands of structural variants
such as base pair insertions, de-
letions, inversions, and gene
copy number variants present in
the human diploid genome. To
date, structural variants have not
been well characterized because
we are only in the early phases of
whole genome sequencing. Their
understanding is additionally
compromised because all se-
quencing that is done today re-
lies on using the human genome
reference template, or rese-
quencing, rather than de novo
assembly. Beyond that, there are
tissue-specific important epige-
netic variations such as patterns
of methylation, histone modifi-
cations, and chromatin state—
all of which are likely contribu-
tors to disease susceptibility
(12). Other differences, such as
protein splicing and folding, dif-
ferences in the individual’s metabolome, also need to be
taken into account. Despite these substantial challenges,
over the last 4 years, there has been an unprecedented
stream of important genomic discoveries illuminating novel
pathways involved in disease biology (13).
These discoveries stem from several recent key advances.
First, large-scale efforts have led to the identification of
approximately 10 million SNPs that carry at least a 5% minor
allele frequency (MAF) and are commonly represented in
populations under study (14). In addition, another 10 million
or more SNPs are considered rare or low frequency because
Abbreviations
and Acronyms
AAA  abdominal aortic
aneurysm
ANGPTL3  angiopoietin-like
3 protein
APOE  apolipoprotein E
CAD  coronary artery
disease
CRP  C-reactive protein
CYP  hepatic cytochrome
GWAS  genome-wide
association studies
IHD  ischemic heart
disease
KIV-2  kringle IV type II
LPA  apolipoprotein (a)
polymorphism
Lp (a)  lipoprotein (a)
molecule
MAF  minor allele
frequency
MI  myocardial infarction
OR  odds ratios
SNP  single nucleotide
polymorphismthey fall below the 5% MAF threshold. In aggregate, these fSNPs represent only 0.5% of the human genome, but are the
most abundant form of human genomic variation (15).
Notably, these SNPs are not inherited independently, but
s “bins” or “blocks” that are in linkage disequilibrium.
urther, the genotype of 1 SNP may be sufficient to infer
he genotype of all other SNPs within a given linkage
isequilibrium block (haplotype), thereby “tagging” an en-
ire region of interest (Fig. 1) (15). Thus, by assaying for
nly 1 million of these tag SNPs, a GWAS is essentially
ssessing hundreds of thousands of independent haplotype
locks for disease and drug response associations. This
ypothesis-free approach in scanning the human genome
as yielded hundreds of reproducible disease susceptibility
arkers in independent cohorts involving tens of thousands
f cases and controls (13).
Second, the striking reduction of costs associated with DNA
equencing have enabled targeted resequencing of genomic
egions thought to be involved in disease and health (16). This
as resulted in the ability to identify rare genetic variants with
MAF of5%, which complement the common susceptibil-
ty SNPs (MAF 5%) established through GWAS (16).
ow, these rare SNPs, present in common, incriminated
aplotype blocks by GWAS, are being assayed for along with
ommon SNPs in more comprehensive GWAS studies of
omplex traits with great early success (17). An exemplary case
s the recent discovery of 2 apolipoprotein (a) (LPA) polymor-
hisms—1 rare and 1 common variant—that when present
ogether confer at least a 250% increase in risk for CAD (17).
his finding was facilitated by data generated from GWAS
nd resequencing of LPA in thousands of individuals with and
ithout CAD.
Along these lines, Musunuru et al. (18) were recently able
o completely sequence more than 16,000 genes in 2 family
embers affected by familial combined hypolipidemia—a
endelian disorder marked by low cholesterol levels and
ifelong protection against CAD. Interestingly, individuals
ffected by the disorder were compound heterozygotes for 2
are nonsense mutations in the angiopoietin-like 3 protein
ANGPTL3). Further, in a separate cohort, a gene dose
ffect from the variants was observed with single allele
arriers having substantially lower low-density lipoprotein
holesterol levels than noncarriers. Notably, ANGPTL3 is
rimarily expressed and secreted in the liver with inactiva-
ion of the gene leading to lower plasma cholesterol in mice.
hus, ANGPTL3 may serve as a valuable new therapeutic
arget for low-density lipoprotein reduction and prevention
f CAD in the future.
Third, novel approaches in genetic association studies
sing “Mendelian randomization” principles have assisted in
rmly establishing the link between key intermediate phe-
otypes (inflammation, plasma lipoproteins, glucose levels)
nd many complex traits (17,19,20). This approach lever-
ges the fact that genes undergo random assortment when
orming gametes and are transferred in unbiased fashion
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475from parent to offspring during the time of conception
(20,21). Thus, a Mendelian randomization study that as-
sesses the influence of a gene product on a biologic outcome
is, in essence, naturally providing the same principle of a
randomized trial but, in some ways, may be considered
superior. Potential confounders of these studies include
additional potential causative genes that may be nearby and
in linkage disequilibrium with gene variants being studied,
as well as population admixture from ancestral populations
that carry different risks for disease and different genotypes.
However, both of these confounders can be easily accounted
for by proper design of such studies.
An ideal application of Mendelian randomization prin-
ciples is well illustrated in a recent publication by Zacho et
al. (22) on C-reactive protein (CRP)—a well-known
marker of inflammation strongly tied to CAD. Notably,
before this study, the question of whether CRP was simply
a marker for CAD or actually contributed to disease
causation remained unanswered. To answer this question,
the investigators assessed 2 independent populations involv-
ing over 50,000 subjects and found that 4 defined CRP gene
polymorphisms with a known influence on plasma CRP
Figure 1. SNPs, Tag SNPs, and Microsatellites as Genomic Markers
(A) Autologous chromosome with evenly spaced microsatellites. (B) Segment
polymorphisms (SNPs) are noted (A, B, C, etc.) within the DNA segment. Tag S
a surrogate for these haplotypes and, more importantly, disease-causing gene
ers of the same genes designated in part B of the ﬁgure. Note that the micros
Reprinted, with permission, from Damani and Topol (10).levels did not predict IHD. Conversely, the relationshipbetween elevated CRP and IHD remained strong, thereby
indicating that lifelong elevation of CRP levels as indicated
by genetic polymorphisms does not confer risk for IHD and
that CRP is simply a marker of and not likely a contributor
to CAD risk.
These seminal findings recently took on greater meaning
with the publication of the high profile JUPITER (Justifi-
cation for the Use of Statins in Prevention: An Intervention
Trial Evaluating Rosuvastatin) (23). In JUPITER, individ-
uals with elevated CRP levels treated with rosuvastatin had
a 44% reduction in IHD events that was independent of
lipid status. Unfortunately, a control group with low CRP
and low low-density lipoprotein was not included in the
study. Nevertheless, when reconciling JUPITER with ge-
netic data on CRP, it is clear that the benefit from
rosuvastatin is most likely secondary to inadvertent decrease
in inflammation and not from a direct reduction in plasma
CRP levels. Moreover, the genetic data on CRP further
validate the previously touted pleiotropic effects of statins
with respect to inflammation reduction and potentially
support the use of statins to prevent CAD in high-risk
patients with elevated CRP levels and normal plasma
xyribonucleic acid (DNA) between microsatellite markers. Single nucleotide
C, H, K) travel with other noted SNPs as blocks (haplotypes) and can serve as
ose proximity. (C) A DNA segment with alternative alleles and genomic mark-
e markers are not as close in proximity to the genes as the noted SNPs.of deo
NPs (
s in cl
atellitlipoproteins.
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476Lipoprotein (a)
The lipoprotein (a) [Lp (a)] molecule is composed of a
low-density lipoprotein that is covalently linked to the
plasminogen-like glycoprotein, apolipoprotein (a) (Fig. 2)
(24). Notably, Lp (a) has been regarded as a putative
cardiovascular risk factor for over 4 decades (24). How-
ever, the extent of its contribution to IHD has been
controversial and unsettled (25). Now, 3 independently
conducted genomic studies have underscored the impor-
tance and clearly defined the role of Lp (a) in CAD and
MI (17,19,26).
The initial confirmatory study was an extensive 3-stage
GWAS (26). In the first stage, the investigators assayed
over 500,000 SNPs in 2,000 cases and controls. Subse-
quently, the most significant SNPs (p  105) were then
validated in a second cohort consisting of 875 CAD cases
and 1,644 controls. Interestingly, a single haplotype on
chromosome 6q26-q27, which encompasses the LPA gene,
remained highly significant and was subsequently validated
in a third stage. The final population-adjusted analysis of all
3 stages demonstrated that 2 LPA haplotypes were highly
significant for CAD (p  1.0  1013, p  1.0  1015)
ith odds ratios (OR) of 1.2 and 1.8, respectively.
In a parallel study that used Mendelian randomization
rinciples, Kamstrup et al. (19) found that common kringle
Figure 2. Lipoprotein (a) Molecule
Lipoprotein (a) consists of an low-density lipoprotein particle and a glyco-
protein molecule, Apo(a), attached to the ApoB-100 moiety of the low-
density lipoprotein particle through a disulﬁde bond. Apo(a) size is deter-
mined by the number of kringle repeats. Reprinted, with permission, from
Danesh and Erqou (24).V type II (KIV-2) copy number polymorphisms in LPA,which are known to influence both LPA particle size and Lp
(a) plasma levels, correlated with a risk for MI (OR: 1.2)
independent of plasma Lp (a) levels (19,27). Further, in a
subgroup analysis of a 9,000-patient prospective cohort with
over 16 years of follow-up, they demonstrated that at-risk
KIV-2 copy number polymorphism carriers had an impres-
sive 150% increase in risk for coronary events.
In the third and final related study, investigators used a
novel cardiac gene chip and assayed for 48,742 common and
rare SNPs from several candidate genes in over 7,000 CAD
cases and controls (17). Remarkably, the LPA locus on
q26-27 that was originally identified in the previously
oted GWAS most strongly correlated with CAD (26).
arriers of a single common variant rs10455872 (MAF 
%) or an independent rare variant rs3798220 (MAF 2%)
had an OR of 1.70 and 1.92, respectively, or a striking 2.5
when carrying both at-risk variants (Fig. 3). Moreover,
these variants were shown to tag individual LPA alleles with
fewer KIV-2 repeats, thereby confirming data linking
smaller LPA isoforms to a heightened risk for CAD (27,28).
Most recently, the European Atherosclerosis Society has
recommended routine screening for Lp (a) levels and
treatment with niacin for individuals with plasma Lp (a)
levels 50 mg/dl (20). However, the findings from the
enomic studies covered here suggest that LPA screening
or susceptibility variants may be a better initial screening
ool for many reasons. Current widely used Lp (a) assays do
ot fully account for important qualitative features including
Figure 3. Association of the LPA Genotype Score With the
Lp(a) Lipoprotein Level and the Risk of Coronary Disease in the
PROCARDIS Cohort
The odds ratios (squares, with the size inversely proportional to the sam-
pling variation) are for the association of the LPA genotype score (no vari-
ant alleles, 1 variant allele, or 2 variant alleles) with the risk of coronary
disease, as measured using “ﬂoating absolute risks,” which summarize the
sampling variation for the 3 genotype scores without the selection of an
arbitrary baseline genotype score. The vertical lines indicate 95% conﬁ-
dence intervals. LPA  apolipoprotein (a) polymorphism; PROCARDIS 
precocious coronary artery disease. Reprinted, with permission, from Clarke
et al. (17).
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477LPA particle size and the number of KIV-2 repeats, and
they are highly variable with respect to sensitivity and
specificity. Further, the consistent and reproducible increase
in risk for CAD in at-risk LPA variant carriers far surpasses
the highly variable and at times conflicting results seen in
the substantial proportion of epidemiological studies con-
ducted to date on plasma Lp (a) levels (25,27,29–31). In
addition, the genetic effect of LPA variants on CAD appears
to be independent of age and sex.
To date, 1 of the most interesting findings on the genetic
basis of CAD has been the discovery of a novel MI risk
locus on chromosome 9p21 (32). In 2007, 4 GWAS
involving over 50,000 cases and controls and 10 indepen-
dent populations reported a robust link between several
SNPs on chromosome 9p21 and MI (16,33–35). Impor-
tantly, about 25% of the populations studied are homozy-
gous carriers of the at-risk variants and harbor close to a 2-fold
increase in risk for MI. Another recent study has illustrated
that a significant gene dosage influence exists with the number
of 9p21 risk alleles directly correlating with CAD severity (36).
Further, these SNPs have also been shown to predict more
progressive CAD, abdominal aortic aneurysm (AAA), and
remarkably, intracranial aneurysm (37,38). This surprising new
finding now raises the possibility that functional effects from
9p21 may stem more from mechanisms related to vascular
remodeling rather than to atherosclerosis.
In another study of over 30,000 AAA cases and healthy
controls, the 9p21 locus was once again linked to AAA (p
1.7  107) (39). However, a new susceptibility allele
rs7025486) in an intron of the gene DAB2IP—a cell cycle
egulator previously linked to many cancers—was also
ignificantly associated with AAA (OR: 1.24, p  1.8 
09). Surprisingly, this same allele also conferred suscep-
ibility to early onset MI, peripheral arterial disease, and
ulmonary embolism (OR: 1.18, 1.14, and 1.2, respec-
ively), thereby further underscoring a common genetic
hread between previously unlinked vascular phenotypes.
Currently, the exact mechanism by which the 9p21 locus
xerts its influence on these various vascular phenotypes
emains unclear. Notably, the at-risk variants lie in a
desert” region of the genome with the closest annotated
enes, CDKN2A and CDKN2B, being 100,000 base pairs
way (32). These tumor suppressor genes are cyclin-
ependent kinase inhibitors with established regulatory
oles in cell-cycle progression and documented antiprolif-
rative effects (32,40). Recently, Visel et al. (41) have
rovided preliminary evidence linking 9p21 SNPs to altered
DKN2A and CDKN2B gene expression. By deleting a
0-kilobase region from mouse chromosome 4, which is
rthologous to the 58-kilobase region at 9p21.3 in humans,
hey found a dramatic reduction in expression of Cdkn2a
nd Cdkn2b in the knockout mice. Further, they observed a
oubling in smooth muscle cell proliferation, enhanced
eight gain, a substantially larger number of tumors, and an dverall increased death rate in the mutant mice when
ompared with wild-type mice. Interestingly, there was no
vidence for increased atherosclerotic plaque burden in the
ortas of the knockout mice.
Although highly informative, these findings raise addi-
ional questions regarding the 9p21 risk locus (32). For
xample, why was there no observed increase of atheroscle-
otic burden in the mutant mice, when this has clearly been
he case in humans? Overall, it appears that the murine
odel may not be fully adequate for precisely defining the
echanistic influence of 9p21 variants on multiple arterial
henotypes. This theory is supported by the only moderate
omology (50%) present between the human and mouse
p21 locus. Additionally, the effects from fully deleting a
0-kilobase region, as Visel et al. (41) did in their mouse
odel, versus carrying a few 9p21 SNPs as humans do,
ould yield entirely different phenotypes. Most recently,
arismendy et al. (42) demonstrated that the 9p21.3 locus
s most likely exerting its effects through key inflammatory
athways triggered by local and long distance gene interac-
ions. In order to determine this, they first examined
ranscription factor binding and chromatin modification
rofiles in various human cell lines, which revealed that the
p21.3 region contains over 30 enhancers — one of the
ighest densities for predicted enhancers in the human
enome. Second, through computational modeling, they
ound that the 9p21.3 SNP rs10757278, which is the SNP
ost consistently associated with coronary artery disease in
revious GWAS, resides within an enhancer site (ECAD9)
nd disrupts the binding of STAT1 — a transcription factor
ritically involved in inflammation and interferon- signal-
ng. These data emphasize the emerging link between
nflammation and a variety of discrete vascular phenotypes
hat were previously thought to be unrelated.
Potential genomic markers of sudden cardiac death are
lso emerging. Recently, Bezzina et al. (43) assessed over
00,000 SNPs in 515 individuals with ventricular fibrilla-
ion and MI and 457 controls with MI alone. Strikingly, the
ost significant associated SNP, rs2824292 (p  2.2 
010) was present in over 50% of cases and conferred an
mpressive 180% increase in risk for ventricular fibrillation.
erhaps most compelling is that the susceptibility allele is
ocated near the gene CXADR, which encodes the Cox-
ackie virus and adenovirus receptor protein. This trans-
embrane tight junction protein has been previously impli-
ated in both virus-mediated cardiomyopathies and in
udden cardiac death in candidate gene-based studies.
dditional mechanistic studies will need to be performed to
recisely define the basis of this variant’s influence on
entricular tachyarrhythmias. However, the genomic under-
innings of ventricular fibrillation illuminated by this study
ay lead to better predictive algorithms and preventive
easures in MI patients at high risk for sudden cardiaceath.
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478Apolipoprotein E
Apolipoprotein E (APOE) polymorphisms have been the
most widely studied genetic risk factors in humans due to
their well-established links to Alzheimer’s dementia, dys-
lipidemia, and CAD (44,45). Carriers of the E4 allele,
which represent approximately 20% of the population of
European ancestry, have higher circulating cholesterol levels
than their common E2 and E3 counterparts (44,46). Most
importantly, these carriers are at increased risk for CAD
(44,46).
First discovered in 1977, APOE4 polymorphisms have
been firmly linked to dyslipidemia and CAD in over 50
studies (44). Several GWAS have now confirmed this
association (47). Further, a decade ago, investigators found
that ApoEIV carriers had reduced survival rates after MI,
which was abolished by treatment with simvastatin (48).
Notably, the derived benefit from statin therapy did not
relate to greater lipid lowering, which, once again, provides
further evidence for a pleiotropic effect of statin use.
Based on these data, it may be possible to use the APOE4
genotype for CAD risk prediction and institution of statin
therapy in patients with moderate risk factors for IHD.
Such a strategy would be suitable for a prospective study, or
if the data were available from large-scale, placebo-controlled
statin trials with multiyear follow-up, validation might be
supported. However, the psychosocial concerns of assessing
APOE status for CAD and the need for disclosure of risk for
Alzheimer’s has, at least in part, limited its use. Importantly, a
recent study demonstrated that disclosing APOE genotype data
to adult children of an affected Alzheimer’s disease parent did
not result in significant anxiety or psychological distress (49).
Thus indicating that current concerns related to APOE4
testing and disclosure may be overblown.
In contrast to the APOE4 pharmacogenetic story, recent
claims that a KIF6 gene variant predicts statin response have
been dubious (50). Surprisingly, over 150,000 KIF6 “Stat-
incheck” tests have been ordered based solely on 3 retro-
spective candidate gene studies that demonstrated a modest
increase in CAD risk (OR: 1.1 to 1.5) (51–53) and another
study that found statin therapy abrogated this enhanced risk
(54). However, several troublesome aspects of KIF6 data
exist. First, unlike APOE, KIF6 is not expressed in the
vasculature and has no known biologic relevance in dyslipide-
mia or CAD (55). Second, none of the over 10 GWAS on
lipids or CAD have linked KIF6 to either phenotype (26,33–
35,47,56–60). Third, a recent well-conducted meta-analysis in
over 17,000 individuals found no link between CAD and KIF6
(61). Thus, although many of the examples herein exemplify
the promises of genomic medicine, the KIF6 story should serve
as a valuable reminder of the pitfalls present when prematurely
adopting a genetic test in clinical practice.Antiplatelet Pharmacogenomics
Adjunctive aspirin and clopidogrel use in the management
of patients with acute coronary syndromes and those receiv-
ing coronary stents has substantially reduced the risk for MI,
stent thrombosis, and death (62–64). However, in 2006, a
variable antiplatelet effect with clopidogrel was observed in
hepatic cytochrome (CYP) 2C19 loss-of-function variant
carriers (65). Now, several large studies involving thousands
of patients have confirmed that genetic resistance to clopi-
dogrel is prevalent even in patients with acute coronary
syndromes (66–69). Importantly, the at-risk variants result in
reduced clopidogrel active metabolite formation, diminished
antiplatelet effect, and a 3-fold increase in risk for stent
thrombosis, MI, and death (66–68,70,71). Additionally, re-
cent studies have also identified a common CYP2C19 gain-of-
function variant that confers a 2-fold increase in risk for
bleeding (Fig. 4) (72). Remarkably, these gain- and loss-of-
function variants are highly common with one-third of Euro-
peans and close to one-half of those with African and Asian
ancestry harboring the at-risk alleles.
Similar to the APOE and LPA variants, the CYP2C19
variants were originally identified through hypothesis-driven
candidate gene studies. Now, Shuldiner et al. (70), through
GWAS, have incontrovertibly confirmed that the predomi-
nant mediator of genetic resistance to clopidogrel is the hepatic
CYP2C19 locus. To determine this, the investigators first
measured platelet aggregation at baseline and within 1 h after
the last dose of clopidogrel on day 7. Subsequently, over
400,000 SNPs were simultaneously assessed in a GWAS of
platelet reactivity. Not surprisingly, the region most signifi-
cantly associated with clopidogrel response clustered around
the CYP2C19 locus. Moreover, CYP2C19 variant carriers had
a striking 345% increase in risk for stent thrombosis, along
Figure 4. CYP2C19*17 Genotypes and Incidence of TIMI Bleedings
Reprinted, with permission, from Sibbing et al. (72). CYP  hepatic
cytochrome; TIMI  Thrombolysis In Myocardial Infarction.
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479with heightened risk MI, and death, which is consistent with
previous candidate gene study results.
The clopidogrel story represents the prototypical scenario
for individualizing medicine based on key pharmacog-
enomic information. It is 1 of the most highly prescribed
drugs in the world and is used routinely to prevent stent
thrombosis, MI, and death in the over 1 million people
receiving coronary stents in the United States annually (73).
ost importantly, alternatives to standard clopidogrel dos-
ng are readily available for individuals resistant to the drug.
hese alternatives include the addition of cilostazol, or the
se of alternative P2Y12 receptor blocking antiplatelet
agents such as prasugrel or ticagrelor (74–77). Further,
genotyping for at-risk CYP2C19 variants can be performed
in patients undergoing coronary stenting and enables iden-
tification of those individuals at greatest risk for thrombotic
complications. These high-risk individuals can then be
closely monitored during the post-stenting period with
platelet function testing to ensure adequate antiplatelet
response. This is especially important given that stent
thrombosis, although only occurring in 2% of patients,
carries a mortality rate of over 40% and occurs most
frequently within hours of stenting (78–80). Consistent
with this line of reasoning, a recently released U.S. Food
and Drug Administration boxed warning has recommended
such an individualized approach to antiplatelet therapy in
patients receiving coronary stents (74).
Another recent key discovery in antiplatelet pharmacog-
enomics relates to the identification of a rare SNP in LPA that
predicts with high accuracy those individuals most likely to
Table 1. Recent Advances in Ischemic Heart Disease Genomics
Gene or Locus Condition
Ex
9p21.3 (CDKN2A, CDKN2B) MI GWAS
AAA
Intracranial aneurysm
PAD
LPA CAD GWAS,
reseq
Enhanced aspirin response
APOE CAD, dyslipidemia GWAS,
reseq
CYP2C19 Stent thrombosis (*2 *5 alleles) GWAS,
reseq
Bleeding (*17 allele)
21q21 (CXADR) Ventricular ﬁbrillation GWAS
DAB2IP Early onset MI GWAS
AAA
PE
PAD
*The odds ratio represents the increased risk for CAD in rs3798220 carriers. The enhanced risk was
AAA abdominal aortic aneurysm; APOE apolipoprotein E; CAD coronary artery disease; CYOR odds ratio; PAD peripheral artery disease; PE pulmonary embolism.benefit from aspirin therapy (81,82). Chasman et al. (81)
reported that the nonsynonymous SNP, rs3798220 (MAF 
3.5%), which encodes for an isoleucine to methionine substi-
tution (Ile4399Met), resulted in an 8-fold increase in Lp (a)
plasma levels and a corresponding 2-fold increase in risk for
MI and stroke. Interestingly, this heightened risk was com-
pletely abrogated in the Ile4399Met carriers by aspirin therapy.
This report is especially timely given recent meta-analysis data
showing an exceedingly small benefit and substantial risk for
bleeding with the nondiscretionary use of aspirin in a primary
prevention setting (83). Moreover, as previously mentioned,
Clarke et al. (17) recently found that the same rare SNP
(rs3798220) conferred a similar relative risk for CAD in a
separate study involving over 7,000 CAD cases and controls.
Unfortunately, this study did not test the aspirin hypothesis.
Along these lines, in a recent publication of the first
clinically annotated whole-genome sequence, over 60 pharma-
cogenetic variants with an immediate influence on drug efficacy
and toxicity were detected in an otherwise healthy 40-year-old
male geneticist who had sequenced his own genome (84).
Notably, his variants included the at-risk LPA variant
(rs3798220), which resulted in a recommendation by the
individual’s physician to initiate aspirin therapy for primary
prevention of CAD.
Caution in Interpreting Negative
SNP Profiling Studies
Earlier this year, Paynter et al. (85) reported on the
prognostic capability of 101 SNPs linked to CAD through
ntal
ds
Effect Size (OR)
(Single Allele)
Effect Size (OR)
(Multiple Alleles) Ref. #
1.2–1.4 1.6–2.0 32–34,37,39
1.31 1.74
1.29 1.72
1.14 —
ate gene,
ng
1.7–1.9 2.5–4.0 17,81
2.2* —
ate gene,
ng
1.1–1.4 1.2–1.6 44,45
ate gene,
ng
3.5 4.6 70,71
1.8 3.2
1.5–1.8 — 43
1.18 — 39
1.21 —
1.20 —
1.14 —
tely abrogated by aspirin therapy.
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480previous GWAS. An integrated “genetic risk score” for
CAD based on the carrier status of these 101 SNPs did
predict a heightened risk for CAD, but failed to incremen-
tally add to models based on traditional risk factors. How-
ever, there are several important limitations of this study
that require addressing. First, all 101 variants received equal
weighting in their model, despite clear differential and more
potent disease-causing effects from variants such as those in
the 9p21 locus, which promotes a washout of any informa-
tive potential of the SNPs assessed. Second, many of the
SNPs were from GWAS that used variable definitions for
CAD cases and healthy controls. Third, some of the most
important known CAD SNPs, such as those in LPA, were
ot included. Fourth, a family history of premature CAD
ontinued to be predictive for the development of CAD
ven after adjustment for the traditional risk factors, indi-
ating important genetic underpinnings of this disease that
ave yet to be fully defined. Finally, a recent study has
ndicated that the simultaneous assessment of all disease-
ssociated SNPs proportionally increases the prediction of
isease heritability (86), thus indicating that current genetic
isk scores must include all relevant rare and common SNPs
including those yet to be discovered) with adequate weight-
ng to accurately portray the individual’s true genetic risk for
isease. To date, no such model has been developed.
uture Directions
Over the last 4 years, the breakneck pace of discoveries into
the genomic underpinnings of complex traits has largely
been enabled by genome-wide assessment of common SNPs
(Table 1). Unfortunately, substantial portions of the heritabil-
ty of many complex traits, including CAD, remain missing.
his missing heritability or “dark matter” of the genome will
ikely be unraveled in incremental fashion in the years ahead
hrough the identification and validation of rare susceptibility
NPs and disease-causing structural variants in properly de-
igned, large-scale, whole-genome sequencing studies (12).
oreover, comprehensive delineation of tissue-specific epige-
etic characteristics such as DNA methylation, histone mod-
fication, and chromatin state will provide additional insight
nto biologic mechanisms of disease. However, access to
rterial and myocardial tissue for epigenetic studies will be
imited, so less-invasive approaches to access these tissues will
e needed. Recent advances in rare cell biology that sequester
irculating endothelial cells from the peripheral blood are
xemplary of such noninvasive approaches (87). Additionally,
he concurrent implementation of proteomic and metabolomic
echnologies in genomic studies will provide vital information
n the biologic alterations present in various disease states,
hile also serving to uncover novel therapeutic targets.onclusions
In summary, the emerging applications in CAD genomics and
pharmacogenomics covered in this review represent a preview of
the transformative discoveries that will continue to surface in the
months and years ahead. The challenge will be in determining
when and how to implement such data into routine clinical
practice. The clopidogrel and LPA scenarios represent 2 areas
where the evidence threshold for individualizing therapy based on
genotype data has been clearly surpassed. However, it will ulti-
mately be the individual clinician that will decide when and how
to use these data. Hence, systematic education and training of
physicians on the benefits and drawbacks to genomic medicine
must be performed for the full potential of the future era of
individualized medicine to be realized.
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